Literature DB >> 14990737

Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus.

Marcel Asper1, Thomas Sternsdorf, Meike Hass, Christian Drosten, Antje Rhode, Herbert Schmitz, Stephan Günther.   

Abstract

The high pathogenicity of Lassa virus is assumed to involve resistance to the effects of interferon (IFN). We have analyzed the effects of alpha IFN (IFN-alpha), IFN-gamma, and tumor necrosis factor alpha (TNF-alpha) on replication of Lassa virus compared to the related, but less pathogenic, lymphocytic choriomeningitis virus (LCMV). Three low-passage Lassa virus strains (AV, NL, and CSF), isolated from humans with mild to fulminant Lassa fever, were tested. Lassa virus replication was inhibited by IFN-alpha and IFN-gamma, but not TNF-alpha, in Huh7 and Vero cells. The degree of IFN sensitivity of a Lassa virus isolate did not correlate with disease severity in human patients. Furthermore, cytokine effects observed for Lassa virus and LCMV (strains CH-5692, Armstrong, and WE) were similar. To address the mechanisms involved in the IFN effect, we used cell lines in which overexpression of IFN-stimulated proteins promyelocytic leukemia protein (PML) and Sp100 could be induced. Both proteins reside in PML bodies, a cellular target of the LCMV and Lassa virus Z proteins. Overexpression of PML or Sp100 did not affect replication of either virus. This, together with the previous finding that PML knockout facilitates LCMV replication in vitro and in vivo (M. Djavani, J. Rodas, I. S. Lukashevich, D. Horejsh, P. P. Pandolfi, K. L. Borden, and M. S. Salvato, J. Virol. 75:6204-6208, 2001; W. V. Bonilla, D. D. Pinschewer, P. Klenerman, V. Rousson, M. Gaboli, P. P. Pandolfi, R. M. Zinkernagel, M. S. Salvato, and H. Hengartner, J. Virol. 76:3810-3818, 2002), describes PML as a mediator within the antiviral pathway rather than as a direct effector protein. In conclusion, the high pathogenicity of Lassa virus compared to LCMV is probably not due to increased resistance to the effects of IFN-alpha or IFN-gamma. Both cytokines inhibit replication which is relevant for the design of antiviral strategies against Lassa fever with the aim of enhancing the IFN response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14990737      PMCID: PMC353741          DOI: 10.1128/jvi.78.6.3162-3169.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production.

Authors:  J M Emeny; M J Morgan
Journal:  J Gen Virol       Date:  1979-04       Impact factor: 3.891

2.  Rapid and simple method for purification of nucleic acids.

Authors:  R Boom; C J Sol; M M Salimans; C L Jansen; P M Wertheim-van Dillen; J van der Noordaa
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

3.  A case-control study of the clinical diagnosis and course of Lassa fever.

Authors:  J B McCormick; I J King; P A Webb; K M Johnson; R O'Sullivan; E S Smith; S Trippel; T C Tong
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

4.  An IkappaB homolog encoded by African swine fever virus provides a novel mechanism for downregulation of proinflammatory cytokine responses in host macrophages.

Authors:  P P Powell; L K Dixon; R M Parkhouse
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

Review 5.  Antiviral actions of interferons.

Authors:  C E Samuel
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

6.  Endemic Lassa fever in Liberia. III. Characterization of Lassa virus isolates.

Authors:  P B Jahrling; J D Frame; S B Smith; M H Monson
Journal:  Trans R Soc Trop Med Hyg       Date:  1985       Impact factor: 2.184

7.  Interferon-modulated expression of genes encoding the nuclear-dot-associated proteins Sp100 and promyelocytic leukemia protein (PML).

Authors:  T Grötzinger; T Sternsdorf; K Jensen; H Will
Journal:  Eur J Biochem       Date:  1996-06-01

8.  Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB.

Authors:  Michael Biermer; Robyn Puro; Robert J Schneider
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  Lethal H5N1 influenza viruses escape host anti-viral cytokine responses.

Authors:  Sang Heui Seo; Erich Hoffmann; Robert G Webster
Journal:  Nat Med       Date:  2002-08-26       Impact factor: 53.440

10.  MENINGITIS IN MAN CAUSED BY A FILTERABLE VIRUS : I. TWO CASES AND THE METHOD OF OBTAINING A VIRUS FROM THEIR SPINAL FLUIDS.

Authors:  T F Scott; T M Rivers
Journal:  J Exp Med       Date:  1936-02-29       Impact factor: 14.307

View more
  40 in total

1.  Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus.

Authors:  Delphine Pannetier; Stéphanie Reynard; Marion Russier; Alexandra Journeaux; Noël Tordo; Vincent Deubel; Sylvain Baize
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections.

Authors:  Markus Mordstein; Eva Neugebauer; Vanessa Ditt; Birthe Jessen; Toni Rieger; Valeria Falcone; Frederic Sorgeloos; Stephan Ehl; Daniel Mayer; Georg Kochs; Martin Schwemmle; Stephan Günther; Christian Drosten; Thomas Michiels; Peter Staeheli
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

3.  Replicon system for Lassa virus.

Authors:  Meike Hass; Uta Gölnitz; Stefanie Müller; Beate Becker-Ziaja; Stephan Günther
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Pathogenic Old World arenaviruses inhibit TLR2/Mal-dependent proinflammatory cytokines in vitro.

Authors:  Melissa W Hayes; Ricardo Carrion; Jerritt Nunneley; Andrei E Medvedev; Maria S Salvato; Igor S Lukashevich
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

5.  Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophages.

Authors:  Xavier Carnec; Sylvain Baize; Stéphanie Reynard; Laure Diancourt; Valérie Caro; Noel Tordo; Michèle Bouloy
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

6.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

Review 7.  The search for animal models for Lassa fever vaccine development.

Authors:  Igor S Lukashevich
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

8.  Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys.

Authors:  Sylvain Baize; Philippe Marianneau; Philippe Loth; Stéphanie Reynard; Alexandra Journeaux; Michèle Chevallier; Noël Tordo; Vincent Deubel; Hugues Contamin
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

9.  T cell-dependence of Lassa fever pathogenesis.

Authors:  Lukas Flatz; Toni Rieger; Doron Merkler; Andreas Bergthaler; Tommy Regen; Mariann Schedensack; Lukas Bestmann; Admar Verschoor; Mario Kreutzfeldt; Wolfgang Brück; Uwe-Karsten Hanisch; Stephan Günther; Daniel D Pinschewer
Journal:  PLoS Pathog       Date:  2010-03-26       Impact factor: 6.823

10.  Development of a new tacaribe arenavirus infection model and its use to explore antiviral activity of a novel aristeromycin analog.

Authors:  Brian B Gowen; Min-Hui Wong; Deanna Larson; Wei Ye; Kie-Hoon Jung; Eric J Sefing; Ramona Skirpstunas; Donald F Smee; John D Morrey; Stewart W Schneller
Journal:  PLoS One       Date:  2010-09-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.